Activated Charcoal Arnica Montana Whole Arsenic Tr
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Activated Charcoal Arnica Montana Whole Arsenic Tr
- Multi-Ingredient Homeopathic Complex: Insufficient Data for Repurposing Evaluation
Multi-Ingredient Homeopathic Complex: Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This submission comprises a 22-ingredient homeopathic/botanical combination — including Activated Charcoal, Arsenic Trioxide, Nitroglycerin, Strophanthus Hispidus, Selenicereus Grandiflorus, and Naja Naja Venom, among others — with no approved indications on record in the US market. The TxGNN pipeline returned no predicted indications, and no clinical trial or literature evidence was retrieved, making a standard repurposing evaluation impossible at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN returned no candidates) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only; in this case, no prediction was generated |
| US Market Status | ✗ Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
The TxGNN model operates on a knowledge graph that maps individual drug entities (identified via DrugBank IDs) to disease nodes. This submission failed at the entity-resolution step for two reasons:
1. No DrugBank ID could be matched. The input string is a semicolon-delimited list of 22 heterogeneous ingredients — ranging from conventional small molecules (Arsenic Trioxide, Nitroglycerin) to botanical extracts (Arnica Montana, Kalmia Latifolia), animal-derived substances (Naja Naja Venom, Pork Heart, Pork Liver), homeopathic nosodes (Human Herpesvirus 4 & 5), and organic acids (Fumaric Acid, Lactic Acid, Malic Acid). The DrugBank query returned one result for the string as a whole but could not resolve it to a single canonical entity, so no graph embedding was generated.
2. No original indication was available as an anchor. The TFDA registry returned zero records. Without a regulatory anchor, the pipeline has no baseline from which to compute repurposing distance. The combination does not appear to be approved or registered under any searchable product name in the US market.
Ingredient-level inspection suggests this may be a homeopathic cardiac remedy: Strophanthus Hispidus (a cardiac glycoside source), Selenicereus Grandiflorus (traditionally indicated for heart weakness in phytotherapy), Spigelia Anthelmia (a classical homeopathic heart remedy), and Nitroglycerin (well-established for angina) all point in this direction. However, this is interpretive and cannot substitute for regulatory data.
US Market Information
No US market authorizations are on record for this combination product. The TFDA query on 2026-03-24 returned zero results.
Safety Considerations
Please refer to the package insert for safety information.
Note: Several individual ingredients in this combination carry known safety signals that would require evaluation before any clinical use:
- Arsenic Trioxide — cardiotoxic (QT prolongation), hepatotoxic; requires ECG monitoring
- Strychnos Ignatii Seed — contains strychnine and brucine; neurotoxic at non-homeopathic doses
- Naja Naja Venom — neurotoxic and cytotoxic at pharmacological doses
- Nitroglycerin — vasodilator; contraindicated with PDE5 inhibitors
No drug-drug interaction data was retrieved for this combination as submitted.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline could not generate any repurposing prediction because the input could not be resolved to a single DrugBank entity, and no regulatory approval records exist to anchor the evaluation. There is no evidence base — clinical, observational, or mechanistic — to assess.
To proceed, the following is needed:
- Clarify the product identity: Provide the brand name, product registration number, or a single active pharmaceutical ingredient (INN) as the primary query entity. If this is a known homeopathic brand (e.g., a Heel or Weleda product), provide that name directly.
- Decompose into individual ingredients: Run separate TxGNN evaluations for pharmacologically active components (e.g., Arsenic Trioxide, Nitroglycerin) that have established DrugBank IDs, rather than submitting the full combination string.
- Obtain TFDA/NDA records: If a regulatory filing exists in any jurisdiction, provide the authorization number so approval status and labeled indications can be confirmed.
- Resolve MOA data: Mechanism of action data (DG002) is missing. For any individual component taken forward, DrugBank API lookup is the recommended source.
- Safety package: TFDA package insert warnings and contraindications (DG001) are blocking. These must be retrieved before any clinical feasibility assessment.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.